Allogeneic hematopoietic stem cell engraftment

Allogeneic hematopoietic stem cell engraftment is the process by which donor HSCs from an allogeneic source home to the recipient’s bone marrow niche and subsequently reconstitute the entire hematopoietic system, including all blood and immune cells[5][7]. Successful engraftment is a critical therapeutic endpoint in allogeneic HSCT for malignancies and other hematologic diseases, requiring both biological compatibility (e.g., HLA matching) and appropriate modulation of host immunity[4]. Engraftment is monitored by recovery of blood counts, donor chimerism studies, and clinical surveillance[6]. Drugs such as G-CSF and plerixafor facilitate mobilization and collection of donor HSCs, while immunosuppressants reduce the likelihood of rejection. Safety concerns include engraftment syndrome, GVHD, and infection risks during hematopoietic recovery[1][7].

Other names

Allogeneic stem cell engraftmentAllogeneic HSC engraftmentEngraftment after allogeneic HSCT

Stem cell mobilization: G-CSF increases stem cells in circulation; CXCR4 inhibition: Plerixafor blocks retention signals for stem cells, facilitating mobilization; Immunosuppression: reduces host immune rejection to allow donor cell engraftment